Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amali Karunathilaka

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|March 13, 2024
Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based ApproachesAndrés Felipe Leal, Angelica María Herreno-Pachón, Eliana Benincore-Flórez, et al.
BMC Nephrology|May 22, 2024
18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income settingRidma Prasadini Karunathilake, Roshan Athula Kumara, Amali Karunathilaka, et al.
Immunity & Ageing : I & A|February 23, 2022
CD161 expression defines new human γδ T cell subsetsAmali Karunathilaka, Samuel Halstrom, Patricia Price, et al.
IJID Regions|October 27, 2025
Longitudinal evaluation of anti-SARS-CoV-2 neutralizing antibody levels in 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccinated kidney transplant population: 18-month follow-upKankanamalage Ridma Prasadini Karunathilake, Roshan Athula Kumara, Amali Karunathilaka, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|March 13, 2024
Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based ApproachesAndrés Felipe Leal, Angelica María Herreno-Pachón, Eliana Benincore-Flórez, et al.
BMC Nephrology|May 22, 2024
18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income settingRidma Prasadini Karunathilake, Roshan Athula Kumara, Amali Karunathilaka, et al.
Immunity & Ageing : I & A|February 23, 2022
CD161 expression defines new human γδ T cell subsetsAmali Karunathilaka, Samuel Halstrom, Patricia Price, et al.
IJID Regions|October 27, 2025
Longitudinal evaluation of anti-SARS-CoV-2 neutralizing antibody levels in 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccinated kidney transplant population: 18-month follow-upKankanamalage Ridma Prasadini Karunathilake, Roshan Athula Kumara, Amali Karunathilaka, et al.
Pageof 1